The full content will be available shortly. Thank you for your patience!
Andrea C. Araujo 1
, Juan G. Cataño 2
, Alejandro González-Motta 3
, Juan C. Galvis 3
, Andrés F. Gutiérrez 4
, Santiago Rodriguez 2
, Martín A. Rondón 5 
1 Department of Urology, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; 2 Department of Urology, Urologic Oncology, Functional Unit of Genitourinary Tumors and Prostate Cancer, Hospital Universitario San Ignacio, Bogotá D.C., Colombia; 3 Department of Radiation Oncology, Hospital Universitario San Ignacio, Bogotá D.C., Colombia; 4 Department of Urology, Urologic Oncology, Fundación Santa Fe de Bogotá, Bogotá D.C., Colombia; 5 Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá D.C., Colombia
*Correspondence: Andrea C. Araujo. Email: andreaaraujo2707@gmail.com
Objective: To evaluate acute and late genitourinary and gastrointestinal toxicity, as well as quality-of-life outcomes, in patients with localized prostate cancer treated with hypofractionated radiotherapy in a Latin American population, given that optimal fractionation for radiotherapy remains under debate and there is a lack of regional evidence describing these outcomes. Method: A prospective cohort study was performed. Patients with localized prostate cancer treated with hypofractionated radiotherapy at the Centro Javeriano de Oncología were included. The main outcome was acute and late genitourinary and gastrointestinal toxicity at 14 days, 3 months, and 1 year. Sexual, bowel, and urinary quality of life was assessed at 3 months, 6 months, and 1 year after completion of radiotherapy. Results: One hundred and seventy-six patients were included. The overall quality of life in physical score showed a decrease at 6 months, while at 3 months and 1 year, no differences were found. In the mental score, no differences were found at any cut-off point, likewise for the quality of life by domains. Regarding urinary and rectal toxicity, both acute and late, no differences were found in any case. Conclusions: Our study shows that there are no relevant negative impacts in terms of general and domain-specific quality of life, as well as for acute and late genitourinary and gastrointestinal toxicity up to 1 year of follow-up, with promising results in terms of oncologic outcomes.
The full content will be available shortly. Thank you for your patience!
The editorial process consists of 6 stages:
1. Reception of the manuscript (indeterminate, depending on whether the author meets the requirements): its objective is to verify that the manuscript complies with the specifications of these instructions for authors and that the submitted documentation is complete.
2. Initial editorial review (maximum 5 business days): its objective is to corroborate the relevance, timeliness, originality, and scientific contribution of the manuscript, as well as the methodological and statistical soundness of the study. At this time, it will be submitted to an electronic plagiarism detection system. Derived from this, a rejected opinion may be obtained, or it will be sent for review by peer researchers.
3. Review by peer researchers (maximum 30 business days): the opinion of at least two experts in the area in question will be obtained, who will evaluate the technical and methodological aspects of the investigation.
4. Editorial review (maximum 7 business days): its objective is to make a decision based on the opinion of peer reviewers. The opinion can be rejected, major changes, minor changes or accepted. In the case of major or minor changes, it will be submitted again for evaluation by the initial peer reviewers.
5. Final edition (6 weeks): its objective is the technical and linguistic edition (and translation), layout of galleys, DOI assignment, and correction by the author.
6. Advanced publication: All manuscripts will be published ahead of print on the journal’s website as soon as they complete the editing process, until they are incorporated into a final issue of the journal.